Published on thinner evidence: weigh the verdict and its sources before you rely on it.
read against 3 sources
date 2026-09-23 (day) read as 2026-09-21 (day, biospace.com)
The company's press release gives the announcement date as 2026-09-21, while BioWorld and ChemDiv date their coverage to 2026-09-23; the company's release is preferred. ChemDiv calls it seed funding in the headline but states in the article that it was pre-seed financing; the amount was not disclosed.
[ BUILT WITH ]·[ SEARCH ]found by Firecrawl search: clean energy startup "pre-seed" funding round·[ SCRAPE ]3 pages read: chemdiv.com, biospace.com, bioworld.com·[ JSON ]round extracted with a schema, grounded to one sentence·[ VERIFY ]correctedread back across 3 sources·[ BRANDING ]logo and colour from the homepage·[ ALEXANDRIA ]firmographics from FullEnrich via Alexandria·[ AGENT ]dossier built by the Firecrawl agent
Published on thinner evidence: weigh the verdict and its sources before you rely on it.
read against 3 sources
date 2026-09-23 (day) read as 2026-09-21 (day, biospace.com)
The company's press release gives the announcement date as 2026-09-21, while BioWorld and ChemDiv date their coverage to 2026-09-23; the company's release is preferred. ChemDiv calls it seed funding in the headline but states in the article that it was pre-seed financing; the amount was not disclosed.
Dossier
[ CHECKED ]
Fetched today
Anacalypsis Therapeutics develops disease-modifying medicines and biomarkers for neurodegenerative diseases, initially Parkinson’s disease, using genetically linked targets and precision neurology.
Founders
Alexia V. Polissidis · Co-founder & Chief Executive Officer
Hardy J. Rideout · Co-founder & Chief Scientific Officer
Founded
2019
Backers
Brain Gain Fund, Michael J. Fox Foundation for Parkinson’s Research (MJFF), egg (enter•grow•go), the Eurobank incubation and acceleration program
Metavallon VC[ LEAD ]